Comparative Pharmacology
Head-to-head clinical analysis: TARGRETIN versus TRETINOIN.
Head-to-head clinical analysis: TARGRETIN versus TRETINOIN.
TARGRETIN vs TRETINOIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective retinoid X receptor (RXR) agonist that modulates gene expression involved in cell differentiation, proliferation, and apoptosis.
Retinoic acid receptor agonist; binds to RAR and RXR nuclear receptors, modulating gene transcription involved in cell differentiation, proliferation, and apoptosis.
300 mg/m2 orally once daily.
Acute promyelocytic leukemia (APL): 45 mg/m2/day orally divided twice daily, as induction therapy.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 3–10 hours) for the parent drug. The active metabolite (bexarotene glucuronide) has a half-life of about 9 hours. Clinically, steady state is reached within 3–5 days.
Clinical Note
moderateTretinoin + Digoxin
"Tretinoin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateAlitretinoin + Digoxin
"Alitretinoin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTretinoin + Digitoxin
"Tretinoin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateAlitretinoin + Digitoxin
"Alitretinoin may decrease the cardiotoxic activities of Digitoxin."
Terminal elimination half-life is 0.5-2 hours for the parent drug, but may be prolonged to 10-12 hours after multiple dosing due to reduced clearance; clinical context: t1/2 is short, requiring frequent or continuous dosing to maintain therapeutic levels.
Primarily metabolized in the liver via CYP3A4; elimination is mainly through hepatobiliary excretion into feces. Renal excretion is minimal (<3% as unchanged drug).
Primarily fecal (approx. 60%) via biliary excretion as metabolites; renal excretion accounts for <15% of a dose as unchanged drug and metabolites.
Category C
Category D/X
Retinoid
Retinoid